AIDS is the late stage clinical manifestation of long-term persistent infection with human immunodeficiency virus type 1 (HIV-1). The natural immune response directed against the virus and against virus-infected cells during the persistent infection usually fails to mediate resolution of the infection. The major immunogen of HIV-1 is gpI60, which is made up of gpl20 and gp4l. There are several obstacles to the development of a safe and effective vaccine against HIV-1; most antibodies elicited after HIV-1 infection or after vaccination with gpl2O are not virus neutralizing, and those that are neutralizing are found in low titers (35) . In addition, gp160 sequences may elicit autoimmune responses and may even induce antibodies that enhance HIV infection and disease progression (15, 27, 28) . Since HIV-1 viruses vary considerably in their genomic sequences, neutralizing antibodies are predominantly isolate specific, and HIV-1 escape mutants emerge under immunological pressure (1, 17, 19, 21, [23] [24] [25] 34) . Another concern is the question of whether an immunized host is able to eliminate infected cells. Most likely, mechanisms involving cytotoxic T cells, T-helper cells, and antibody-dependent cellular cytotoxicity would be more effective in clearing infected cells. Therefore, identification of epitopes that induce cross-neutralizing antibodies and/or cell-mediated immunity might be crucial for the development of an effective HIV-1 vaccine.
Neutralizing antibodies have been shown to be directed to various regions of HIV-1 (for a review, see reference 22 ). An encouraging finding was the observation that approximately 60% of current HIV-1 isolates have a conserved sequence within the V3 loop on gp120 (16) . Immunization with this conserved peptide (GPGRAF) was reported to elicit neutralizing antibodies to divergent isolates carrying this conserved six-amino-acid sequence (14) . However, under immune pressure by antibodies to the V3 loop, escape mutants emerge readily (18, 19, 21) . There is also evidence that the antigenicity of the loop is not determined solely by its primary amino acid sequence, since emergence of neutralization-resistant variants * Corresponding author. Electronic mail address: iam@mail.
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is not always accompanied by a change in the primary amino acid sequence of the V3 domain (21) . Another conserved region capable of inducing cross-neutralizing antibodies by means of a synthetic peptide was localized on the putative cytoplasmic domain of gp4l (7). This region was also shown to induce broadly neutralizing HIV-1 antibodies when presented by an engineered poliovirus chimera (10) . Recently, identification of peptides which react with neutralizing and fusioninhibiting human sera suggested the presence of additional neutralizing epitopes on gp4l (2, 33) .
In previous work, we established a human monoclonal antibody (MAb 2F5) directed against gp4l. This MAbs. Production and characterization of human MAbs 2F5 and iBI are described in detail elsewhere (3, 4) . Briefly, hybridomas were generated by a combined polyethylene glycol-electrofusion method (29) . As polylinker BamHI-EcoRI sites of plasmid pGEX-2T (Pharmacia, Milton Keynes, Buckinghamshire, England), which allowed fusion of the NH2-terminal ends of the gp4l fragments with the COOH-terminal ends of glutathione S-transferase (GST). The different gp4l fragments ( Fig. 1 and 2) were obtained either by polymerase chain reaction (PCR) amplification using the appropriate primers or through hybridization of oligonucleotides corresponding to gp4l. Primers and oligonucleotide sequences were based on the SwissProt data base entry ENV$HIV10, which corresponds to gpl6O of HIV-1 isolate BH10. In addition, fusion peptides with sequences from genetically divergent HIV-1 isolates corresponding to amino acid positions 662 to 667 on the envelope glycoprotein were made (Fig. 3B) . The resulting GST fusion proteins were expressed in Escherichia coli as described previously (31) and purified on glutathione-Sepharose 4B columns (Pharmacia). Samples of 200 ng (Fig. la) or 100 ng ( Fig. lb and 2 ) of these fusion proteins were analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and Western blotting (immunoblotting) with human MAb 2F5, using a procedure modified from that of Towbin et al. (32) .
Epitope mapping by phage-displayed hexapeptides. Human 
Amino acid sequences found to be recognized by MAb 2F5.
Screening was done by using a random hexapeptide library expressed on the surface of filamentous phage.
with MAb 2F5 were identified by immunoblotting. Figure 1 shows Western blots of fusion peptides with overlapping fragments of gpl60 of HIV-1. In contrast to constructs that contain amino acids 597 to 677 (Fig. la, lane 2 with DKWA being the core sequence. On the basis of this finding, a mutational analysis of the six-amino-acid region was performed. It was found that replacement of position 662, 663, or 667 resulted in a slight reduction, whereas mutation of position 665 resulted in dramatic reduction, in binding to human MAb 2F5. A loss of binding to MAb 2F5 was observed when position 664 or 666 was changed (Fig. 2) . No significant reduction occurred when mutations were introduced outside the ELDKWA sequence (data not shown). In addition, a peptide mapping study using a random hexapeptide library expressed on protein III of a filamentous phage was performed. The hexapeptide sequences shown in Fig. 4 represent additional variations of the 2F5 epitope of HIV-1 which are recognized by human MAb 2F5. Five of 17 isolated phage clones that bound to MAb 2F5 contained the sequence DKWA, and 13 of 17 isolated phage clones contained the sequence DKW, in the hexapeptide sequence.
Blocking of syncytium inhibition. To demonstrate that the epitope sequence is biologically active, syncytium inhibition "Number of isolates containing this sequence in the data bases that were screened (SwissProt, translated GenBank, and Human Retroviruses and AIDS). Determined by immunoblotting. " Determined as described in Materials and Methods. ND, not determined. assays in the presence of a synthetic peptide and GST fusion peptides containing the sequence ELDKWA were performed. Both the synthetic ELDKWA peptide and the ELDKWA fusion peptide abolished syncytium inhibition activity mediated by MAb 2F5 in a dose-dependent manner (Fig. 3A) . In contrast, syncytium inhibition mediated by human MAb IBI, which recognizes a different epitope than does MAb 2F5, was not affected by the synthetic peptide. The GST control also showed no significant blocking of syncytium inhibition (Fig.  3A) . In addition, syncytium inhibition assays in the presence of GST fusion peptides containing the corresponding sequences of HIV-1 isolates with amino acid differences in that region (Table 1) were performed. Two of the variant fusion peptides containing the sequences ALDKWA and QLDKWA were reactive in this assay (Fig. 3B) .
Sequence comparison. We were interested in the conservation of the ELDKWA epitope sequence in different HIV-1 isolates. Three data bases were used for sequence comparison: SwissProt, translated GenBank, and Human Retroviruses and AIDS. The ELDKWA sequence was found to be highly conserved among otherwise divergent HIV-1 isolates. Out of 79 sequences, 57 (72%) contained the ELDKWA epitope sequence and 69 (87%) contained the DKWA epitope core sequence (Table 1) . In contrast, the conserved sequence of the V3 loop GPGRAF was found in only 61% of HIV-I sequences in these data bases.
Immune selection and sequence analysis of the 2F5 epitope region. Cells were infected with HIV-1 isolates MN, RF, and III" and cultivated in the presence of MAb 2F5. The epitope region corresponding to positions 1927 to 2013 on gpl6( from extracellular virus was sequenced before and after cultivation of infected cells in the presence of human MAb 2F5. For HIV-1 isolates MN and RF, no escape mutants were detected in the presence of 2F5 over pcriods of 5 and 9 months, respectively. Since PCR analysis of chromosomal DNA revealed that these cells contained integrated provirus (data not shown), cells were then further cultivated in the absence of human MAb 2F5. TPA and PHA were used to stimulate the production of infectious virus. Further cultivation of MNinfected cells in the absence of MAb 2F5 for 6 months did not result in the production of infectious virus. In contrast, abolishing the antibody pressure from RF-infected cells resulted in release of infectious virus after a latency period of 14 weeks. This virus showed the same neutralization-sensitive phenotype as the original RF virus stock did. Sequence analysis of virions obtained by this procedure revealed that the epitope sequence had remained unchanged. As shown in Fig. 5 , four clones obtained from the original virus stock (RF, Cl to C4) and four clones from virions obtained after 2F5 antibody pressure release (RF/2F5 Cl to C4) that were sequenced showed the identical genotype. All sequences were obtained from independent cDNAs. In contrast to cells infected in the presence of MAb 2F5 with HIV-1 isolates MN and RF, which did not result in the generation of escape mutants, cells exposed to (Fig. 5 , IIIB Cl to C3) and one clone had a silent T-to-C change in position 2004 (Fig. 5, IIIB C4) (18, 19, 21, 24) . Microheterogeneity in HIV-1 virus stocks, the high error rate of the reverse transcriptase, and recombination are thought to be responsible for the generation of these antigenic variants (8, 11, 13, 26 (23a) and showed no amino acid changes in the epitope sequence (Fig. 5) . However, as expected from our sequence comparison (Table 1) There are several reasons to believe that the identified epitope is a promising candidate for inclusion into an HIV-1 subunit vaccine. The specific abrogation of syncytium inhibition activity of human MAb 2F5 suggests that the peptide sequence by itself is able to mimic the epitope as it exists on gp4l. Also, this sequence might be able to elicit cross-reactive antibodies with properties which are similar to those of human MAb 2F5. Although a conformational influence on binding affinity by amino acids outside this region cannot be excluded, gp41-GST fusion peptides containing mutations outside the ELDKWA sequence showed unaltered binding activities. In addition, a recombinant chimeric influenza virus containing the 2F5 epitope inserted in antigenic site B of the hemagglutinin is very efficiently neutralized by MAb 2F5, suggesting that the epitope is determined by its primary sequence (19a) . The high degree of conservation of the epitope in different HIV isolates suggests that antibodies induced by this epitope sequence would be directed against a wide variety of divergent HIV-1 isolates. Since the ELDKWA epitope sequence is only minimally immunogenic in the context of a large molecule like gpl60, the induction of high levels of antibodies directed against the 2F5 epitope may be highly desirable and lead to partial protection against infections by HIV-1 isolates.
